UA105073C2 - Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень - Google Patents

Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень

Info

Publication number
UA105073C2
UA105073C2 UAA201206559A UAA201206559A UA105073C2 UA 105073 C2 UA105073 C2 UA 105073C2 UA A201206559 A UAA201206559 A UA A201206559A UA A201206559 A UAA201206559 A UA A201206559A UA 105073 C2 UA105073 C2 UA 105073C2
Authority
UA
Ukraine
Prior art keywords
composition
fractalkine
antibody
inflammatory disorders
treating inflammatory
Prior art date
Application number
UAA201206559A
Other languages
English (en)
Russian (ru)
Inventor
Міюкі Нісімура
Йосімаса Сакамото
Тецу КАВАНО
Тосіо Імаі
Original Assignee
ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43922220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA105073(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. filed Critical ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД.
Publication of UA105073C2 publication Critical patent/UA105073C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід належить до антитіла або його фракталкінзв'язуючого фрагмента, які специфічно зв’язують фракталкін, фармацевтичної композиції, що містить антитіло або його фракталкінзв'язуючий фрагмент, способу отримання антитіла або його фракталкінзв'язуючого фрагмента, фармацевтичної композиції, що містить антитіло або його фракталкінзв'язуючий фрагмент, нуклеїнової кислоти, вектора, клітини-хазяїна та застосування для терапевтичних цілей.
UAA201206559A 2009-10-30 2010-10-28 Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень UA105073C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25652109P 2009-10-30 2009-10-30
PCT/JP2010/069653 WO2011052799A1 (en) 2009-10-30 2010-10-28 Compositions and methods for treating inflammatory disorders

Publications (1)

Publication Number Publication Date
UA105073C2 true UA105073C2 (uk) 2014-04-10

Family

ID=43922220

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201206559A UA105073C2 (uk) 2009-10-30 2010-10-28 Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень

Country Status (33)

Country Link
US (1) US8932592B2 (uk)
EP (1) EP2493930B1 (uk)
JP (2) JP5631991B2 (uk)
KR (2) KR101627605B1 (uk)
CN (1) CN102597003B (uk)
AR (2) AR078796A1 (uk)
AU (1) AU2010312408B2 (uk)
BR (1) BR112012010266A2 (uk)
CA (1) CA2778895C (uk)
CL (2) CL2012001143A1 (uk)
CY (1) CY1121167T1 (uk)
DK (1) DK2493930T3 (uk)
ES (1) ES2698389T3 (uk)
HR (1) HRP20181973T1 (uk)
HU (1) HUE041952T2 (uk)
IL (1) IL219470A (uk)
JO (1) JO3437B1 (uk)
LT (1) LT2493930T (uk)
MX (1) MX2012005052A (uk)
MY (1) MY158481A (uk)
NZ (1) NZ599779A (uk)
PE (1) PE20121645A1 (uk)
PH (1) PH12012500828A1 (uk)
PL (1) PL2493930T3 (uk)
PT (1) PT2493930T (uk)
RS (1) RS58142B1 (uk)
RU (1) RU2569109C2 (uk)
SI (1) SI2493930T1 (uk)
SM (1) SMT201800637T1 (uk)
TW (1) TWI414308B (uk)
UA (1) UA105073C2 (uk)
WO (1) WO2011052799A1 (uk)
ZA (1) ZA201203002B (uk)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
PL3221346T3 (pl) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
EP3159007A1 (en) 2015-10-19 2017-04-26 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating rheumatoid arthritis
JP2017154975A (ja) * 2016-02-29 2017-09-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
JP2018070473A (ja) * 2016-10-26 2018-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチを治療するための医薬組成物
JP2018177701A (ja) * 2017-04-14 2018-11-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
WO2020214166A1 (en) * 2019-04-17 2020-10-22 The Governors Of The University Of Alberta Treatment of autoimmune liver disease
JP7550142B2 (ja) 2019-04-23 2024-09-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチ治療のためのバイオマーカー
WO2021118999A1 (en) * 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder
CN113087795B (zh) * 2019-12-23 2025-06-10 上海普铭生物科技有限公司 针对趋化因子cx3cl1的抗体及其应用
JPWO2022092183A1 (uk) 2020-10-30 2022-05-05
CN121537534B (zh) * 2026-01-22 2026-04-07 华中科技大学同济医学院附属协和医院 靶向cx3cl1的嵌合抗原受体-巨噬细胞及在gjb2突变相关遗传性耳聋治疗中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
JP3925663B2 (ja) 1995-06-30 2007-06-06 持田製薬株式会社 抗Ｆａｓリガンド抗体および該抗体を用いた測定法
US6114507A (en) 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
US6096312A (en) 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
US6548654B1 (en) 1996-01-24 2003-04-15 Schering Corporation DNA encoding mammalian CX3C chemokine genes
US7115379B1 (en) 1996-01-24 2006-10-03 Schering Corporation Anti-mammalian CX3C cytokine antibodies
US6566503B2 (en) 1996-01-24 2003-05-20 Schering Corporation Mammalian CX3C chemokine
WO1997027299A1 (en) 1996-01-24 1997-07-31 Schering Corporation Mammalian cx3c chemokine genes
US6043086A (en) * 1996-05-07 2000-03-28 Millenium Biotherapeutics, Inc. Neurotactin and uses therefor
WO1997042224A1 (en) 1996-05-07 1997-11-13 Millennium Biotherapeutics, Inc. Neurotactin and uses therefor
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
AU771946B2 (en) 1998-08-31 2004-04-08 Oregon Health And Science University Prevention of cell migration initiation with CMV US28 receptor antagonists
JP2001218581A (ja) 1999-11-30 2001-08-14 Eisai Co Ltd モノクローナル抗体の作製法
US6677321B1 (en) 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
AU2000273378A1 (en) 2000-02-18 2001-08-27 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US20020192212A1 (en) 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
JP4263391B2 (ja) * 2001-03-19 2009-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
ATE439131T1 (de) 2001-08-30 2009-08-15 Chemocentryx Inc Bicyclische verbindungen als hemmer der chemokin- bindung an us28
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
EP1520586A1 (en) 2003-09-30 2005-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibition of fractalkine or of its receptor for the treatment of atopic allergic diseases
EP1671648A4 (en) 2003-10-02 2009-07-08 Eisai R&D Man Co Ltd PREVENTION AND TREATMENT OF GVHD
WO2005033115A1 (en) 2003-10-07 2005-04-14 Astrazeneca Ab New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
CA2580981C (en) * 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Stabilized human igg4 antibodies
ES2641815T3 (es) 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Tratamiento para enfermedades inflamatorias
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
WO2008052108A2 (en) * 2006-10-26 2008-05-02 Centocor Ortho Biotech Inc. Methods for use in human-adapting monoclonal antibodies
MX2010002683A (es) * 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.

Also Published As

Publication number Publication date
CL2015000114A1 (es) 2015-04-10
DK2493930T3 (en) 2018-12-17
AR109533A2 (es) 2018-12-19
BR112012010266A2 (pt) 2016-12-06
MY158481A (en) 2016-10-14
KR20120104560A (ko) 2012-09-21
JP2013509158A (ja) 2013-03-14
CA2778895A1 (en) 2011-05-05
HRP20181973T1 (hr) 2019-01-25
US20120213799A1 (en) 2012-08-23
KR20160066055A (ko) 2016-06-09
WO2011052799A1 (en) 2011-05-05
CN102597003A (zh) 2012-07-18
ES2698389T3 (es) 2019-02-04
US8932592B2 (en) 2015-01-13
ZA201203002B (en) 2013-06-26
HUE041952T2 (hu) 2019-06-28
AR078796A1 (es) 2011-12-07
RU2012122203A (ru) 2013-12-10
SI2493930T1 (sl) 2018-12-31
IL219470A0 (en) 2012-06-28
CA2778895C (en) 2018-08-07
PL2493930T3 (pl) 2019-03-29
MX2012005052A (es) 2012-05-29
CY1121167T1 (el) 2020-05-29
KR102099596B1 (ko) 2020-04-10
KR101627605B1 (ko) 2016-06-07
JP5631991B2 (ja) 2014-11-26
EP2493930B1 (en) 2018-09-19
AU2010312408B2 (en) 2015-07-09
PE20121645A1 (es) 2012-12-06
TW201127401A (en) 2011-08-16
EP2493930A1 (en) 2012-09-05
RS58142B1 (sr) 2019-02-28
EP2493930A4 (en) 2013-12-04
SMT201800637T1 (it) 2019-01-11
AU2010312408A1 (en) 2012-06-21
CN102597003B (zh) 2016-03-23
JP2015027304A (ja) 2015-02-12
IL219470A (en) 2017-10-31
RU2569109C2 (ru) 2015-11-20
PT2493930T (pt) 2018-11-29
TWI414308B (zh) 2013-11-11
JO3437B1 (ar) 2019-10-20
PH12012500828A1 (en) 2013-01-07
LT2493930T (lt) 2019-01-10
NZ599779A (en) 2014-03-28
CL2012001143A1 (es) 2012-10-05

Similar Documents

Publication Publication Date Title
CY1122978T1 (el) Αντισωματα εναντι-vla-4
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
CY1122278T1 (el) Αντι il-36r αντισωματα
CA2813849C (en) Secukinumab for use in the treatment of ankylosing spondylitis
CL2016002340A1 (es) Proteínas de unión al antígeno cd27l; ácido nucleico que la codifica; vector de expresión; célula huésped recombinante; composición que la comprende; su uso para tratar cáncer, trastornos autoinmunitarios o inflamatorios; y método para elaborar un conjugado anticuerpo cd27l-fármaco (divisional sol. n° 699-14).
MX369148B (es) Agentes de unión kir3dl2.
EA201690503A1 (ru) Антитела
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
EA201492101A1 (ru) Антитела против fcrn
BR112014000263A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno do mesmo, molécula de ácido nucleico, e, composição farmacêutica
EA200901421A1 (ru) Антитела к il-25
UA117364C2 (uk) Похідні аматоксину
CL2013001403A1 (es) Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
IL198379A (en) Human antibodies and antibodies that bind sphingosine-1-phosphate, their encoded nucleic acids, and their preparations and methods for treating the disease
BR112014019611A2 (pt) agentes de ligação mica
PH12017500864A1 (en) Anti-notch1 antibodies
WO2011020783A3 (en) Targeted immunoconjugates
EA201892774A1 (ru) Антитела
MY158481A (en) Compositions and methods for treating inflammatory disorders
WO2014004549A3 (en) Anti-mesothelin binding proteins
MX2009008410A (es) Elementos de aglutinacion para moleculas de ige.
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
PH12015501687A1 (en) Novel binding proteins from pcsk9
MX2014014218A (es) Moleculas de union il-6.